Work

Long-term safety and efficacy of ISTH0036 – a selective TGF-β2 blocking antisense oligonucleotide in preclinical and Phase 1 clinical studies.

Year: 2021

Type: article

Source: Investigative Ophthalmology & Visual Science

Authors: René Rückert, Marion R. Munk, Katja Wosikowski, Michel Janicot

Institution: Isarna Therapeutics (Germany)

Language: English

Topic: Retinal Diseases and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,850

OpenAlex ID: W3185389468

FWCI:

Cites:

Cited by:

Related to: 10